JP2011105738A5 - - Google Patents

Download PDF

Info

Publication number
JP2011105738A5
JP2011105738A5 JP2011010997A JP2011010997A JP2011105738A5 JP 2011105738 A5 JP2011105738 A5 JP 2011105738A5 JP 2011010997 A JP2011010997 A JP 2011010997A JP 2011010997 A JP2011010997 A JP 2011010997A JP 2011105738 A5 JP2011105738 A5 JP 2011105738A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
pharmaceutically acceptable
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011010997A
Other languages
English (en)
Japanese (ja)
Other versions
JP5400812B2 (ja
JP2011105738A (ja
Filing date
Publication date
Priority claimed from GBGB0412769.2A external-priority patent/GB0412769D0/en
Application filed filed Critical
Publication of JP2011105738A publication Critical patent/JP2011105738A/ja
Publication of JP2011105738A5 publication Critical patent/JP2011105738A5/ja
Application granted granted Critical
Publication of JP5400812B2 publication Critical patent/JP5400812B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011010997A 2004-06-08 2011-01-21 バニロイドアンタゴニストとして有用なキナゾリノン誘導体 Expired - Lifetime JP5400812B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0412769.2 2004-06-08
GBGB0412769.2A GB0412769D0 (en) 2004-06-08 2004-06-08 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007526311A Division JP4703650B2 (ja) 2004-06-08 2005-06-08 バニロイドアンタゴニストとして有用なキナゾリノン誘導体

Publications (3)

Publication Number Publication Date
JP2011105738A JP2011105738A (ja) 2011-06-02
JP2011105738A5 true JP2011105738A5 (enExample) 2012-03-08
JP5400812B2 JP5400812B2 (ja) 2014-01-29

Family

ID=32696854

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007526311A Expired - Lifetime JP4703650B2 (ja) 2004-06-08 2005-06-08 バニロイドアンタゴニストとして有用なキナゾリノン誘導体
JP2011010997A Expired - Lifetime JP5400812B2 (ja) 2004-06-08 2011-01-21 バニロイドアンタゴニストとして有用なキナゾリノン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007526311A Expired - Lifetime JP4703650B2 (ja) 2004-06-08 2005-06-08 バニロイドアンタゴニストとして有用なキナゾリノン誘導体

Country Status (29)

Country Link
US (4) US7960399B2 (enExample)
EP (1) EP1755606B2 (enExample)
JP (2) JP4703650B2 (enExample)
KR (2) KR20100101017A (enExample)
CN (1) CN1956721B (enExample)
AT (1) ATE376833T1 (enExample)
AU (2) AU2005251476C1 (enExample)
BR (1) BRPI0511933B8 (enExample)
CA (1) CA2567821C (enExample)
CY (1) CY1107846T1 (enExample)
DE (1) DE602005003128T3 (enExample)
DK (1) DK1755606T4 (enExample)
EC (2) ECSP067067A (enExample)
ES (1) ES2293584T5 (enExample)
GB (1) GB0412769D0 (enExample)
HR (1) HRP20070577T4 (enExample)
IL (1) IL179532A (enExample)
MA (1) MA28685B1 (enExample)
MX (1) MXPA06014249A (enExample)
NO (1) NO338181B1 (enExample)
NZ (1) NZ551630A (enExample)
PL (1) PL1755606T5 (enExample)
PT (1) PT1755606E (enExample)
RU (2) RU2449995C2 (enExample)
SG (1) SG153811A1 (enExample)
SI (1) SI1755606T2 (enExample)
TN (1) TNSN06405A1 (enExample)
WO (1) WO2005120510A1 (enExample)
ZA (1) ZA200609634B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
ZA200901163B (en) 2006-08-23 2010-08-25 Neurogen Corp 2-Phenoxy pyrimidinone analogues
CA2668579A1 (en) * 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
WO2009010529A1 (en) 2007-07-18 2009-01-22 Novartis Ag Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
US8915362B2 (en) 2008-10-08 2014-12-23 Ultimed, Inc. Sharps container
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
WO2014138302A1 (en) * 2013-03-05 2014-09-12 University Of Notre Dame Quinazolinone antibiotics
US10016425B2 (en) 2016-11-03 2018-07-10 King Saud University Anti-ulcerative colitis compound
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
TWI878266B (zh) 2019-02-15 2025-04-01 愛爾蘭商博士倫愛爾蘭有限公司 治療眼表痛之方法
US20220162170A1 (en) * 2019-02-15 2022-05-26 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
WO2022029656A1 (en) 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
CN116456986A (zh) * 2020-11-17 2023-07-18 苏州晶云药物科技股份有限公司 一种喹唑啉酮衍生物的新晶型及其制备方法
AR125196A1 (es) 2021-03-26 2023-06-21 Novartis Ag Derivados de ciclobutilo 1,3-sustituidos y sus usos
CN120112515A (zh) 2022-09-21 2025-06-06 博士伦爱尔兰有限公司 Trpv1拮抗剂的结晶多晶型形式及其制剂
KR20250030194A (ko) 2023-08-24 2025-03-05 코웨이 주식회사 출수 장치

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US220227A (en) * 1879-10-07 Improvement in stri klng-movements for clocks
US95650A (en) * 1869-10-12 Improvement in machines for bending sheet-metal for cornices
US49728A (en) * 1865-09-05 Improvement
US82365A (en) * 1868-09-22 thompson
DE239090C (enExample) 1906-11-01
US2749344A (en) 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
DE1224316B (de) 1961-03-18 1966-09-08 Beiersdorf & Co Ag P Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen
US3515787A (en) * 1962-06-27 1970-06-02 Squibb & Sons Inc Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones
DE1232152B (de) * 1962-06-27 1967-01-12 Heyden Chem Fab Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten
GB1003802A (en) * 1963-06-04 1965-09-08 Searle & Co Pyrimidinone derivatives
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US3317388A (en) 1964-11-20 1967-05-02 Wallace & Tiernan Inc Methods for treating pain
US3864362A (en) 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
BE793594A (fr) 1972-01-03 1973-07-02 Pfizer Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants
GB1495305A (en) 1975-09-12 1977-12-14 Pfizer Ltd 3-phenyl-4-oxo-4h-benzopyran derivatives
US4501755A (en) 1981-05-01 1985-02-26 Pennwalt Corporation Isoflavones useful as anti-inflammatory agents
JPS59128376A (ja) * 1983-01-13 1984-07-24 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
SU1262927A1 (ru) 1985-01-09 1997-11-20 Институт физико-органической химии и углехимии АН УССР Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина
JPS62201882A (ja) 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
JPS62193605A (ja) * 1986-02-20 1987-08-25 Toray Ind Inc 半透性複合膜の製造方法
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5294617A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5284853A (en) 1993-04-23 1994-02-08 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0635263A3 (en) 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
HUT68558A (en) 1993-07-20 1995-06-28 Chinoin Gyogyszer Es Vegyeszet Method for preparing isoflavon derivatives
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
JPH07258224A (ja) 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd 二環性化合物
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
DE69616993T2 (de) * 1995-03-14 2002-07-04 Novartis Ag, Basel Trisubstituierte phenyl derivate
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
CA2254974A1 (en) 1996-05-20 1997-11-27 Mark Goulet Antagonists of gonadotropin releasing hormone
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
IT1289154B1 (it) 1997-01-03 1998-09-29 Chiesi Farma Spa Derivati di isoflavone loro preparazione e loro impiego terapeutico
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
CA2298540A1 (en) 1997-08-20 1999-02-25 David J. Julius Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP1047711B1 (en) 1998-01-22 2003-08-20 The Regents of the University of California Nucleic acid sequences encoding capsaicin receptors
BR9908275A (pt) 1998-02-25 2000-10-24 Genetics Inst Inibidores de enzimas fosfolipase
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ES2253208T3 (es) * 1999-02-22 2006-06-01 Pacific Corporation Analogos de vaniloide que contienen farmacoforos de resiniferatoxina como ponentes agonistas del receptor de vaniloide y analgesicos, composiciones y utilizaciones de los mismos.
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
AU4742101A (en) 2000-03-17 2001-10-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6723730B2 (en) 2000-07-20 2004-04-20 Neurogen Corporation Capsaicin receptor ligands
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
FR2815033B1 (fr) 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
JP4259877B2 (ja) 2000-12-11 2009-04-30 アムジエン・インコーポレーテツド Ｃｘｃｒ３アンタゴニスト
KR20030083755A (ko) 2001-03-26 2003-10-30 노파르티스 아게 동통 치료를 위한 바닐로이드 수용체 길항제로서의 용도를위한 융합 피리딘 유도체
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
TW200401770A (en) † 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
AU2003281346B2 (en) 2002-07-05 2007-04-05 F. Hoffmann-La Roche Ag Quinazoline derivatives
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
WO2004041755A2 (en) 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
EP1611112B1 (en) 2003-02-11 2012-08-22 Vernalis (Cambridge) Limited Isoxazole compounds as inhibitors of heat shock proteins
WO2004078719A1 (ja) 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
AU2004290626A1 (en) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
NZ549046A (en) 2004-02-13 2010-06-25 Banyu Pharma Co Ltd Fused-ring 4-oxopyrimidine derivative
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AU2006244027A1 (en) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2009010529A1 (en) 2007-07-18 2009-01-22 Novartis Ag Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists

Similar Documents

Publication Publication Date Title
JP2011105738A5 (enExample)
JP2012111758A5 (enExample)
JP2013532130A5 (enExample)
JP2012107057A5 (enExample)
JP2009149903A5 (enExample)
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
JP2011518833A5 (enExample)
JP2011510079A5 (enExample)
JP2011168603A5 (enExample)
JP2013532687A5 (enExample)
JP2013014622A5 (enExample)
JP2009535462A5 (enExample)
JP2015522045A5 (enExample)
JP2013032389A5 (enExample)
JP2013508347A5 (enExample)
JP2012045397A5 (enExample)
JP2012126725A5 (enExample)
JP2009545527A5 (enExample)
JP2017537066A5 (enExample)
JP2014507446A5 (enExample)
ME02558B (me) Inhibitori replikacije virusa gripa
JP2014503607A5 (enExample)
JP2010529196A5 (enExample)
JP2011037885A5 (enExample)
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона